Table 1.
Baseline Characteristics by Trial and Double Positivity
| POSIBA |
PULSE |
|||||
|---|---|---|---|---|---|---|
| Non-DP (N=158) | DP (N=23) | P Value⁎ | Non-DP (N=30) | DP (N=37) | P Value⁎ | |
| BRAF mutated, N (%) | 16 (10) | 4 (17) | .29 | 2 (7) | 5 (14) | .45 |
| Female, N (%) | 46 (29) | 7 (30) | .99 | 12 (40) | 10 (27) | .30 |
| Age, mean (SD) | 62 (11) | 67 (7) | .031 | 63 (8) | 64 (8) | .61 |
| Primary tumor location, N (%) | .98 | .47 | ||||
| Ascending colon | 28 (18) | 4 (17) | 2 (7) | 3 (8) | ||
| Transverse colon | 13 (8) | 1 (4) | 1 (3) | 5 (14) | ||
| Descending colon | 12 (8) | 2 (9) | 3 (10) | 3 (8) | ||
| Sigma | 65 (41) | 11 (48) | 15 (50) | 12 (32) | ||
| Rectum | 40 (25) | 5 (22) | 9 (30) | 14 (38) | ||
| Stage (at diagnosis), N (%) | .77 | .88 | ||||
| I | 1 (1) | 0 | 0 | 0 | ||
| II | 12 (8) | 1 (4) | 1 (3) | 2 (5) | ||
| III | 32 (20) | 3 (13) | 5 (17) | 4 (11) | ||
| IV | 113 (72) | 19 (83) | 24 (80) | 31 (84) | ||
| Surgery of primary tumor, N (%) | 89 (56) | 12 (52) | .82 | 20 (67) | 24 (65) | .99 |
| ECOG-PS, N (%) | .012 | .61 | ||||
| 0 | 110 (70) | 9 (39) | 16 (53) | 22 (59) | ||
| 1 | 45 (28) | 14 (61) | 13 (43) | 15 (41) | ||
| 2 | 3 (2) | 0 | 1 (3) | 0 | ||
| Number of metastatic organs, N (%) | .30 | .33 | ||||
| 0 | 0 | 0 | 0 | 2 (5) | ||
| 1 | 79 (50) | 15 (65) | 13 (43) | 16 (43) | ||
| >2 | 79 (50) | 8 (35) | 17 (57) | 19 (51) | ||
| Liver metastasis, N (%) | .87 | .93 | ||||
| No liver metastasis | 35 (22) | 5 (22) | 7 (23) | 10 (27) | ||
| <=3, <=5 cm | 28 (18) | 5 (22) | 3 (10) | 4 (11) | ||
| >3 or >5 cm | 95 (60) | 13 (57) | 20 (67) | 23 (62) | ||
| Node metastasis, N (%) | 50 (32) | 7 (30) | .99 | 9 (30) | 12 (32) | .99 |
| Lung metastasis, N (%) | 48 (30) | 2 (9) | .043 | 11 (37) | 14 (38) | .99 |
| Peritoneal metastasis, N (%) | 23 (15) | 4 (17) | .75 | 9 (30.0) | 8 (22) | .57 |
| Administered therapy, N (%) | .18 | |||||
| FOLFOX+cetuximab | 89 (56) | 9 (39) | NA | NA | ||
| FOLFIRI+cetuximab | 69 (44) | 14 (61) | NA | NA | ||
| FOLFOX+panitumumab | NA | NA | 30 (100) | 37 (100) | ||
| Leucocytes, mean (SD) | 8.3 (3.3) | 8.9 (3.7) | .39 | 9.8 (7.1) | 8.2 (2.5) | .23 |
| Hemoglobin, mean (SD) | 13.8 (9.2) | 11.9 (1.6) | .023 | 12.9 (1.7) | 12.4 (1.5) | .15 |
| Platelets, mean (SD) | 282 (104) | 298 (140) | .60 | 298 (144) | 296 (120) | .96 |
| ALP, mean (SD) | 148 (122) | 179 (177) | .44 | 166 (208) | 219 (237) | .34 |
| LDH, mean (SD) | 465 (457) | 632 (1246) | .56 | 683 (814) | 446 (415) | .16 |
| CEA, mean (SD) | 267 (732) | 708 (1772) | .26 | 502 (1212) | 838 (3609) | .61 |
ALP, alkaline phosphatase; CEA, carcinoembryonic antigen; DP, double positivity; ECOG-PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; SD, standard deviation.
⁎
Fisher’s exact test